

KFIN/GXP/JUN/2021 July 7, 2021

Mr. Ajay Nadkarni M/s. GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended June 30, 2021.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended June 30, 2021.

Description of	Opening	Received during the	Attended/Resolved	Pending as on
Complaint	Balance as on	Period 01.04.2021	during the Period	30.06.2021
	01.04.2021	to 30.06.2021	01.04.2021 to	
			30.06.2021	
Non-receipt of	NIL	11	11	NIL
Dividend				
Non-receipt of	NIL	NIL	NIL	NIL
Annual reports				
Non receipt of	NIL	01	01	NIL
share certificates				
SEBI	NIL	NIL	NIL	NIL
Stock Exchange	NIL	02	02	NIL
Total	NIL	14	14	NIL

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Private Limited

Rajitha Cholleti Asst. General Manager

KFin Technologies Private Limited

(Formerly known as "Karvy Fintech Private Limited")

Registered & Corporate Office

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500(Ph : +91 40 6716 2222, 7961 1000 | https://www.kfintech.com | CIN : U72400TG2017PTC117649